Boston Partners’s Omnicell OMCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.8M Buy
531,305
+83,763
+19% +$3.51M 0.02% 385
2025
Q4
$20.8M Buy
+447,542
New +$16.4M 0.02% 368
2015
Q3
Sell
-85,842
Closed -$3.24M 728
2015
Q2
$3.24M Buy
85,842
+630
+0.7% +$23K ﹤0.01% 572
2015
Q1
$2.99M Sell
85,212
-7,220
-8% -$238K ﹤0.01% 576
2014
Q4
$3.06M Sell
92,432
-1,075
-1% -$33.2K ﹤0.01% 596
2014
Q3
$2.56M Buy
93,507
+2,060
+2% +$56.4K ﹤0.01% 606
2014
Q2
$2.63M Hold
91,447
﹤0.01% 603
2014
Q1
$2.62M Buy
91,447
+780
+0.9% +$21.3K ﹤0.01% 596
2013
Q4
$2.31M Sell
90,667
-865
-0.9% -$20.7K ﹤0.01% 604
2013
Q3
$2.17M Sell
91,532
-135,497
-60% -$3.02M 0.01% 593
2013
Q2
$4.67M Buy
+227,029
New +$4.19M 0.01% 488

Other funds holding OMCL

Boston Partners's OMCL Position: Q1 2026 in Review

Boston Partners increased its Omnicell (OMCL) stake by 19% in Q1 2026, buying an estimated $3.51M and bringing the position to 531,305 shares worth $17.8M. The position accounts for 0.02% of the portfolio, ranked #385.

Boston Partners first reported a position in OMCL in Q2 2013 and has held it in 11 quarters since. The position peaked at $20.8M in Q4 2025. 272 funds tracked by Wall St. Rank hold OMCL as of Q1 2026.

  • Boston Partners held 531,305 shares of Omnicell worth $17.8M as of Q1 2026.
  • Boston Partners bought 83,763 Omnicell shares in Q1 2026, an estimated $3.51M.
  • Omnicell made up 0.02% of Boston Partners's portfolio in Q1 2026, its #385 holding.
  • Boston Partners first reported a position in Omnicell in Q2 2013 and has held it in 11 quarters since.
  • Boston Partners's Omnicell position peaked at $20.8M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Omnicell as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.